GLP-1 Receptor Agonist Cessation Before Surgery
For patients taking GLP-1 receptor agonists for weight loss, stop the medication for at least three half-lives before elective surgery; for patients with type 2 diabetes, consult endocrinology regarding the risks and benefits of this cessation period, as the decision requires balancing aspiration risk against glycemic control deterioration.
Specific Timing by Medication
The most recent multidisciplinary consensus from 2025 1 and supporting guidelines [@2-11@] recommend a three half-life cessation period to clear approximately 88% of the drug. This translates to:
- Weekly semaglutide (Ozempic/Wegovy): 21 days (3 weeks) before surgery
- Weekly tirzepatide (Mounjaro): 15 days before surgery
- Weekly dulaglutide (Trulicity): 13-14 days before surgery
- Daily liraglutide (Victoza): 3 days before surgery
- Daily lixisenatide (Lyxumia): 9 hours before surgery
Critical Distinction: Diabetes vs. Weight Loss
The evidence strongly supports different approaches based on indication [@2-11@]:
For Weight Loss Patients (Non-Diabetic)
Hold for at least three half-lives before surgery. The risks clearly outweigh benefits in this population, as there is no glycemic control concern and higher doses used for weight management may cause more prolonged gastric stasis 2.
For Type 2 Diabetes Patients
Mandatory endocrinology consultation to weigh:
- Risk of pulmonary aspiration from delayed gastric emptying
- Risk of perioperative hyperglycemia and loss of cardiovascular protection
- Need for bridging diabetes therapy during cessation period
The 2025 consensus acknowledges that in diabetic patients, benefits of GLP-1 therapy in the perioperative period (improved glycemic control, lower insulin requirements, reduced hypoglycemia risk, improved cardiovascular outcomes) may outweigh delayed gastric emptying concerns 1.
Evidence Limitations and Controversies
Important caveat: A 2026 study found that 42% of patients who stopped weekly GLP-1 agonists for ≥7 days still had increased residual gastric content on ultrasound, compared to 24% in controls 3. This suggests the recommended cessation periods may not consistently ensure an empty stomach, though the study was underpowered to reach statistical significance.
The evidence base remains insufficient—there are no high-quality prospective studies definitively establishing optimal cessation timing or true aspiration risk 2.
High-Risk Situations Requiring Enhanced Precautions
Implement full aspiration risk mitigation if patients have:
- Recently started medication or increased dose
- Active nausea, vomiting, or abdominal distention
- Unable to hold medication for three half-lives
- Concurrent medications delaying gastric emptying (opioids, proton pump inhibitors, tricyclic antidepressants)
Risk Mitigation Strategy Algorithm
If medication held for three half-lives AND patient asymptomatic:
- Proceed with standard fasting guidelines
- Consider gastric ultrasound if any clinical concern
If medication NOT held for three half-lives OR symptomatic patient:
- Consider postponing elective surgery
- If proceeding:
- Clear liquid diet for extended period before fasting
- Preoperative prokinetic (metoclopramide or erythromycin)
- Point-of-care gastric ultrasound to assess residual volume
- Rapid sequence intubation
- Consider pre-emptive gastric decompression in very high-risk cases
Practical Implementation
Document at preoperative assessment:
- Specific GLP-1 medication and dose
- Date started and last dose taken
- Any gastrointestinal symptoms
- Other medications affecting gastric emptying
- Previous gastroesophageal surgery
The American Society of Anesthesiologists' earlier recommendation to hold daily doses the day before and weekly doses one week before surgery 1 is now considered insufficient by more recent evidence, which supports the three half-life approach as more physiologically sound [@2-11@].